Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Decellmatrix is a biotechnology company focused on the development of regenerative medicine products using decellularized extracellular matrix (dECM) technology. Based in Jiaxing, China, the company produces biomimetic scaffolds that retain the natural architecture and signaling molecules of tissue, facilitating superior integration and healing. Their primary product lines target wound management, hernia repair, and orthopedic reconstruction. Decellmatrix operates a state-of-the-art manufacturing facility compliant with GMP standards to support its growing portfolio of tissue engineering solutions. The company's platform technology allows for the creation of tissue-specific matrices that promote functional recovery across various clinical indications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang Decellmatrix Biotech.